PPT Slide
Alfimeprase Phase 2 Trial: PAO
Design: Multi-center, open-label, dose-escalation study
Doses: 0.1, 0.3 and 0.6 mg/kg
~100-150 patients across 20 centers in the U.S., Europe and South Africa
Lead investigators are Dr. Kenneth Ouriel of the Cleveland Clinic and Dr. Jacob Cynamon of the Montefiore Medical Center
Endpoints: Rate of clot lysis Safety Clinical events
Timeline: Dosing commenced June 2003